This article is more than 5 years old. Information may no longer be current.

pSivida enters partnership for sustained-release glaucoma drug development

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

pSivida has signed an agreement with an unnamed global pharmaceutical company to develop two glaucoma drugs using its proprietary sustained-release technology, according to a company press release.

The partnership includes $750,000 in upfront payments to pSivida for initial development and $200,000 in potential additional payments, the release said.

The agreement comes after positive results in preclinical studies that showed extended release of a drug for up to 6 months with the pSivida technology.

“This agreement extends the strong working relationship between the two organizations,” Nancy Lurker, president and CEO of pSivida, said in the release. “Glaucoma is one of the major causes of blindness, and many patients are not compliant with administering the commonly prescribed treatment of daily drops. Our proprietary sustained-release technology, combined with glaucoma drugs, has the potential to provide new dosing options for patients.”